ISMELIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Ismelin, and what generic alternatives are available?
Ismelin is a drug marketed by Novartis and is included in one NDA.
The generic ingredient in ISMELIN is guanethidine monosulfate. There are two drug master file entries for this compound. Additional details are available on the guanethidine monosulfate profile page.
Summary for ISMELIN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 41 |
Patent Applications: | 3,536 |
Formulation / Manufacturing: | see details |
DailyMed Link: | ISMELIN at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for ISMELIN
US Patents and Regulatory Information for ISMELIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novartis | ISMELIN | guanethidine monosulfate | TABLET;ORAL | 012329-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Novartis | ISMELIN | guanethidine monosulfate | TABLET;ORAL | 012329-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |